<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901871</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021-0091</org_study_id>
    <nct_id>NCT04901871</nct_id>
  </id_info>
  <brief_title>Remimazolam Bolus for General Anesthesia</brief_title>
  <official_title>ED50 and ED95 of Remimazolam Intravenous Bolus on the Loss of Consciousness in Patients Undergoing General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is important to estimate the adequate dose of remimazolam intravenous bolus injection to&#xD;
      induce the loss of consciousness. We will determine the ED50 and ED95 of remimazolam&#xD;
      intravenous bolus on the loss of consciousness in patients undergoing general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Actual">July 26, 2021</completion_date>
  <primary_completion_date type="Actual">July 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loss of consciousness within 5 minutes</measure>
    <time_frame>At 5 minutes after infusion</time_frame>
    <description>Loss of consciousness will be evaluated at 5 minutes after infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to loss of consciousness</measure>
    <time_frame>At 5 minutes after infusion (time to loss of consciousness)</time_frame>
    <description>Time to loss of consciousness will be assessed at 5 minutes after infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>At 5 minutes after infusion</time_frame>
    <description>Blood pressure will be measured at 0, 1, 2, 3, 4, 5 minutes after infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>At 5 minutes after infusion</time_frame>
    <description>Heart rate will be measured at 0, 1, 2, 3, 4, 5 minutes after infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedline</measure>
    <time_frame>At 5 minutes after infusion</time_frame>
    <description>Sedline will be measured at 0, 1, 2, 3, 4, 5 minutes after infusion.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Loss of Consciousness</condition>
  <arm_group>
    <arm_group_label>1 (0.02 mg/kg, age&lt;65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.02 mg/kg will be infused in patients aged&lt;65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 (0.07 mg/kg, age&lt;65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.07 mg/kg will be infused in patients aged&lt;65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 (0.12 mg/kg, age&lt;65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.12 mg/kg will be infused in patients aged&lt;65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 (0.17 mg/kg, age&lt;65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.17 mg/kg will be infused in patients aged&lt;65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5(0.22 mg/kg, age&lt;65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.22 mg/kg will be infused in patients aged&lt;65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6(0.27 mg/kg, age&lt;65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.27 mg/kg will be infused in patients aged&lt;65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 (0.02 mg/kg, age≥65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 (0.07 mg/kg, age≥65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 (0.12 mg/kg, age≥65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.12 mg/kg will be infused in patients aged≥65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 (0.17 mg/kg, age≥65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11 (0.22 mg/kg, age≥65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 (0.27 mg/kg, age≥65)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.02 mg/kg, age&lt;65</intervention_name>
    <description>Remimazolam of 0.02 mg/kg will be infused in patients aged&lt;65.</description>
    <arm_group_label>1 (0.02 mg/kg, age&lt;65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.07 mg/kg, age&lt;65</intervention_name>
    <description>Remimazolam of 0.07 mg/kg will be infused in patients aged&lt;65.</description>
    <arm_group_label>2 (0.07 mg/kg, age&lt;65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.12 mg/kg, age&lt;65</intervention_name>
    <description>Remimazolam of 0.12 mg/kg will be infused in patients aged&lt;65.</description>
    <arm_group_label>3 (0.12 mg/kg, age&lt;65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.17 mg/kg, age&lt;65</intervention_name>
    <description>Remimazolam of 0.17 mg/kg will be infused in patients aged&lt;65.</description>
    <arm_group_label>4 (0.17 mg/kg, age&lt;65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.22 mg/kg, age&lt;65</intervention_name>
    <description>Remimazolam of 0.22 mg/kg will be infused in patients aged&lt;65.</description>
    <arm_group_label>5(0.22 mg/kg, age&lt;65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.27 mg/kg, age&lt;65</intervention_name>
    <description>Remimazolam of 0.27 mg/kg will be infused in patients aged&lt;65.</description>
    <arm_group_label>6(0.27 mg/kg, age&lt;65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.02 mg/kg, age≥65</intervention_name>
    <description>Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.</description>
    <arm_group_label>7 (0.02 mg/kg, age≥65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.07 mg/kg, age≥65</intervention_name>
    <description>Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.</description>
    <arm_group_label>8 (0.07 mg/kg, age≥65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.12 mg/kg, age≥65</intervention_name>
    <description>Remimazolam of 0.12 mg/kg will be infused in patients aged≥65</description>
    <arm_group_label>9 (0.12 mg/kg, age≥65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.17 mg/kg, age≥65</intervention_name>
    <description>Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.</description>
    <arm_group_label>10 (0.17 mg/kg, age≥65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.22 mg/kg, age≥65</intervention_name>
    <description>Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.</description>
    <arm_group_label>11 (0.22 mg/kg, age≥65)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.27 mg/kg, age≥65</intervention_name>
    <description>Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.</description>
    <arm_group_label>12 (0.27 mg/kg, age≥65)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 19 years old or older, with American Society of Anesthesiologists&#xD;
             Physical Status 1-3, and scheduled for general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients scheduled for liver surgery&#xD;
&#xD;
          2. Uncontrolled hypertension&#xD;
&#xD;
          3. Uncontrolled diabetes mellitus&#xD;
&#xD;
          4. Liver disease&#xD;
&#xD;
          5. Kidney disease&#xD;
&#xD;
          6. Intolerance or hypersensitivity to benzodiazepine&#xD;
&#xD;
          7. Addiction&#xD;
&#xD;
          8. Glaucoma&#xD;
&#xD;
          9. Heart failure&#xD;
&#xD;
         10. Peripheral vascular disease&#xD;
&#xD;
         11. Obstuctive lung disease&#xD;
&#xD;
         12. Patients scheduled for regional anesthesia before general anesthesia&#xD;
&#xD;
         13. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Woo Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>GangnamSeveracne Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Dong Woo Han</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Unconsciousness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

